Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBIn an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE …
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 · In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a second-generation …
About Us - Targeted Oncology
WEBAbout Us. Through our digital and print media platforms, Targeted Healthcare Communications offers a dedicated website and publication as well as a number of multichannel programs focused on precision medicine in oncology. Targeted Therapies in Oncology is dedicated to providing oncology healthcare professionals with leading edge …
Association Partnerships - Targeted Oncology
WEBTargeted Oncology™ has partnered with leading national oncology associations, state oncology societies, and community cancer centers to bring oncologists the most important news in cancer research and the latest in best treatment practices. Is your organization missing from this list? Reach out to Leyla Cakici, Strategic Alliance Partnership …
Clinical Potential of onCARlytics Under Exploration in Solid Tumors
WEBAug 4, 2021 · Research in the solid tumors arena around the combination of the oncolytic virus technology CF33-CD19 (onCARlytics) and the CD19-targeting CAR placental-derived T-cell therapy CyCART-19, is underway to explore it’s clinical potential in this patient population, according to an announcement from collaborators Imugene Ltd. and …
Cemiplimab Upholds Efficacy in 3-Year Follow-up for Advanced …
WEBJul 1, 2020 · According to the 3-year follow-up, the trial demonstrated a clinically meaningful improvement with cemiplimab in patients with advanced cutaneous squamous cell carcinoma. The overall response rate (ORR) was 46.1%, which included a complete response (CR) rate of 16.1%. The median time to CR was 11.2 months, and the duration …
Future Directions for the Treatment of mCRPC - Targeted Oncology
WEBOct 19, 2021 · MRI shows lack of metastasis and node involvement (cT2bN0M0) His ECOG PS is 1. Treatment. In Feb. 2017, patient was treated with radical prostatectomy (RP) with nerve sparing surgery and there were no complications. PSA levels go down to 0.3 ng/ml post-operatively but rise to 1.5 ng/ml within 3 months.
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets …
WEBAug 16, 2024 · The pivotal phase 3 inMIND trial (NCT04680052) of tafasitamab-cxix (Monjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody in combination with lenalidomide (Revlimid) and rituximab (Rituxan) vs lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma (FL) met its …
Looking to the Future of Ovarian Cancer Treatment - Targeted …
WEBApr 14, 2021 · Paclitaxel/carboplatin + bevacizumab was initiated q3 weeks for 6 cycles. At 14-months CA-125 had increased. Cisplatin/gemcitabine was initiated, PR. Initiated niraparib maintenance. An expert in ovarian cancer considers the future of ovarian cancer treatment, the use of PARP inhibitors and overcoming PARP resistance, and the …